Cost-effectiveness of different exercise intensities during oncological treatment in the Phys-Can RCT

Anna-Karin Ax, Magnus Husberg, Birgitta Johansson, Ingrid Demmelmaier, Sveinung Berntsen, Katarina Sjövall, Sussanne Börjeson, Karin Nordin & Thomas Davidson

To cite this article: Anna-Karin Ax, Magnus Husberg, Birgitta Johansson, Ingrid Demmelmaier, Sveinung Berntsen, Katarina Sjövall, Sussanne Börjeson, Karin Nordin & Thomas Davidson (2023): Cost-effectiveness of different exercise intensities during oncological treatment in the Phys-Can RCT, Acta Oncologica, DOI: 10.1080/0284186X.2023.2200149

To link to this article: https://doi.org/10.1080/0284186X.2023.2200149

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 19 Apr 2023.

Submit your article to this journal

Article views: 1009

View related articles

View Crossmark data
Cost-effectiveness of different exercise intensities during oncological treatment in the Phys-Can RCT

Anna-Karin Ax, Magnus Husberg, Birgitta Johansson, Ingrid Demmelmaier, Sveinung Bernsten, Katarina Sjövall, Sussanne Börjeson, Karin Nordin, and Thomas Davidson

Department of Oncology, Linköping University, Linköping, Sweden; Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Sport Science and Physical Education, University of Agder, Kristiansand, Norway; Faculty of Health Sciences, Kristianstad University, Kristianstad, Sweden

ABSTRACT

Background: Cost-effectiveness is important in the prioritisation between interventions in health care. Exercise is cost-effective compared to usual care during oncological treatment; however, the significance of exercise intensity to the cost-effectiveness is unclear. In the present study, we aimed to evaluate the long-term cost-effectiveness of the randomised controlled trial Phys-Can, a six-month exercise programme of high (HI) or low-to-moderate intensity (LMI) during (neo)adjuvant oncological treatment.

Methods: A cost-effectiveness analysis was performed, based on 189 participants with breast, colorectal, or prostate cancer (HI: n = 99 and LMI: n = 90) from the Phys-Can RCT in Sweden. Costs were estimated from a societal perspective, and included cost of the exercise intervention, health care utilisation and productivity loss. Health outcomes were assessed as quality-adjusted life-years (QALYs), using EQ-5D-5L at baseline, post intervention and 12 months after the completion of the intervention.

Results: At 12-month follow-up after the intervention, the total cost per participant did not differ significantly between HI (€27,314) and LMI exercise (€29,788). There was no significant difference in health outcome between the intensity groups. On average HI generated 1.190 QALYs and LMI 1.185 QALYs. The mean incremental cost-effectiveness ratio indicated that HI was cost effective compared with LMI, but the uncertainty was large.

Conclusions: We conclude that HI and LMI exercise have similar costs and effects during oncological treatment. Hence, based on cost-effectiveness, we suggest that decision makers and clinicians can consider implementing both HI and LMI exercise programmes and recommend either intensity to the patients with cancer during oncological treatment to facilitate improvement of health.

Introduction

As resources are limited in health care, information on cost-effectiveness of alternative interventions is needed. It is important to consider the opportunity costs of resources used, which is the value of the best alternative use of the same resources. A cost-effectiveness analysis, considering both costs and health outcomes of interventions, is an important tool in the decision-making process when prioritising between interventions or when implementing new interventions in health care. Further, the concept of quality-adjusted life-years (QALY), which combines values of the health state with the duration of time in that state, is an established health outcome that allow comparisons between different interventions in health care, such as exercise programmes in cancer care [1].

There is strong evidence that exercise improves health-related quality of life (HRQoL) and physical function, and reduces fatigue, anxiety and depressive symptoms during and after oncological treatments [2–5]. Exercise may also reduce hospital stays [6,7], decrease sick leave rates [8], and improve survival [9], although more studies are needed to confirm this. Supervised exercise seems to be more effective than unsupervised [3], but entails additional costs. Interventions with combined endurance and resistance training, two to three sessions per week, for at least 12 weeks have demonstrated effect on HRQoL [2]. However, there is insufficient evidence on which exercise intensity is most effective to improve the HRQoL during oncological treatment. While higher exercise intensity leads to additional physical health benefits in general [10], one study showed that patients with cancer prefer low intensity exercise [11]. However, from a public health perspective, the greatest health gains are achieved when reaching an impact in a larger population or with lasting effects [10]. The health outcome of different exercise intensities during oncological
treatment in relation to its costs in the long-term is thus important information for the decision makers.

The few cost-effectiveness analyses performed on exercise interventions during oncological treatment show benefits compared to usual care; however, the results are inconsistent due to heterogeneity with regard to health systems, payment structures, intervention characteristics, cancer populations and follow-up durations [12–14]. Furthermore, cost-effectiveness analyses focussing on different intensities are limited. In a study by Van Waart et al. (2017) comparing usual care to high or low exercise intensity, high was considered cost effective, while low was not considered cost effective, compared to usual care [15]. Though, no comparison of the cost-effectiveness between the different exercise intensities was made. In another study by Kampshoff et al. high intensity exercise was considered cost effective compared to low-to-moderate intensity. However, the exercise programme was performed after chemotherapy [16]. Thus, more cost-effectiveness analyses with exercise interventions during oncological treatment comparing high versus low intensity is requested [12].

The Phys-Can (Physical Training and Cancer) RCT evaluated six months of combined supervised resistance training and home-based endurance training of high-intensity (HI) or low-to-moderate intensity (LMI) [17]. At post-intervention, HI was slightly more beneficial compared to LMI regarding muscle strength, cardiorespiratory fitness and physical fatigue (main outcome), although the differences were not considered clinically important for physical fatigue. There were no differences between groups regarding overall HRQoL, anxiety, depression, functioning in daily life or sleep. At 12-month follow-up after the intervention, there were no differences in total costs [18], or in HRQoL [19] between the exercise intensities. Still, it remains to explore QALYs and hence evaluate the cost-effectiveness between the exercise intensities. In the present study, the aim was to evaluate the long-term cost-effectiveness of an exercise programme of HI or LMI during (neo)adjuvant oncological treatment.

Method

Research design

A cost-effectiveness analysis was performed from a societal perspective with an 18-month time horizon (6 months intervention and 12 months follow-up), based on the data from the Phys-Can RCT. The design including sample size calculations is previously described in detail [20,21]. CHEERS 2022 statement checklist was applied to guide this report [22].

Study sample

Briefly, participants were recruited at three university hospitals in Sweden from 2015 to 2018. Inclusion criteria were patients with breast, colorectal or prostate cancer, aged ≥18 years and scheduled for neoadjuvant and/or adjuvant oncology treatment. Exclusion criteria were health conditions that might contraindicate high-intensity exercise (e.g., heart failure, chronic obstructive pulmonary disease, orthopaedic conditions, or neurological disorders). After completion of baseline measurements, participants were stratified by cancer diagnosis and hospital, and randomly assigned to one of four conditions: LMI exercise, LMI exercise with behaviour change support (BCS), HI exercise, or HI exercise with BCS. The present study only included participants who had completed EQ-5D-5L (see Data Collection) at the 12-month follow-up (n = 189 of 577, 33%; Figure 1). Those who completed EQ-5D-5L were older, had larger proportions of retired participants, and men with prostate cancer, together with lower proportions of participants on sick leave and women with breast cancer receiving chemotherapy, compared to participants who did not complete EQ-5D-5L. This study was approved by the Swedish Ethical Review Authority in Uppsala, Sweden (Ref.no 2014/249) and was conducted in accordance with the Helsinki Declaration. Informed consent was obtained from all participants.

The exercise intervention

The six-month exercise intervention consisted of supervised resistance training and home-based endurance training and was initiated when the oncological treatment began, presented in detail elsewhere [17,20]. The resistance training was performed twice a week at a public gym and consisted of three exercises for the upper extremities and three for the lower extremities. Four additional exercises were advised for the trunk and pelvic floor. The HI group performed one weekly session of 3 x 6 repetition maximum (RM) (2 min rest between sets), and one weekly session of 3 x 10 RM (1 min rest between sets). The LMI group performed one weekly session 3 x 12 repetitions at 50% of 6 RM (2 min between sets), and one weekly session of 3 x 20 repetitions at 50% of 10 RM (1 min rest between sets). For the endurance training, the HI group performed interval sessions twice a week with 2 min of exercise (e.g., running, cycling, walking uphill) at 80–90% heart rate reserved (HRR) followed by 2 min of active rest (e.g., walking). The number of intervals increased from 5 intervals, until max 10 during the intervention period. The LMI group performed 150 weekly minutes of endurance training (walking, cycling) in bouts of minimum 10 min at 40–50% of HRR. Half of the participants in the HI and in the LMI group received additional BCS. In the present study, we focussed on differences between the exercise intensities since additional BCS did not improve health outcomes at post-intervention [17]. The exercise was performed according to a standardised protocol. Coaches (physiotherapists and personal trainers) were educated to provide the intervention. The exercise performed by the participants was monitored by the coaches to follow adherence and progression according to the protocol. Research staff monitored that the coaches followed the intervention protocol.

Data collection

Background characteristics

Participants reported sociodemographic data and comorbidities at baseline. Medical background data were retrieved
from the medical records and the Swedish National Quality Register.

Cost measures
Societal costs included the costs of the exercise intervention, health care utilisation, and productivity loss [18]. Data were collected for 6 months prior to baseline measurement and up to 12 months after completion of the exercise intervention. The costs for the exercise intervention were estimated from invoices and included labour costs for the coaches (including their education and exercise supervision); time worked plus overheads, fitness centre membership fees, maximal oxygen uptake (VO2 max) tests, and heart rate monitors. Travel costs were considered out-of-pocket money for the participants and were compensated by mileage according to the Swedish Tax Agency in 2019 [23]. Health care costs included outpatient visits (except for primary care), hospitalisation and prescribed medication. Health care utilisation was retrieved from the Swedish National Board of Health and Welfare [24] and each visit was applied with costs according to the Swedish NordDRG pricelists [25]. Cost of the prescribed medications were estimated using market prices [26]. Productivity loss included days absent from paid work (sick-leave and disability pension) and were obtained from the Swedish Social Insurance Agency [27]. In Sweden, the first 14 days of sick leave are paid by the employer, which means we don’t have data on periods shorter than 15 calendar days, but we have added the first 14 days for periods longer than that. The human capital approach was used to value the average productivity costs of full-time employees including all taxes and social fees from 2019 (€4550) [28].

Figure 1. CONSORT flow chart of participants through the Phys-Can RCT cost-effectiveness study. HI: high-intensity exercise; LMI: low-to-moderate intensity exercise.
and recalculated as full-time equivalent days. We did not discount any costs since the time horizon was only 18 months. Cost was calculated in SEK converted to Euros using an exchange rate of €1 = SEK 9.963 (28 October 2021) [29].

**Health outcomes**

The health outcome QALYs gained were estimated using EQ-5D-5L [30]. EQ-5D-5L health state consists of five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with a five-level severity scale of no, slight, moderate, severe, and extreme/unable to [19]. The EQ-5D-5L health state index, which is based on these five dimensions, was converted to a health state value ranging from 0 (dead) to 1 (full health). Primarily, we mapped the EQ-5D-5L to EQ-5D-3L [31] and used the UK value set by Burström et al. [32]. Secondarily, we used the Swedish value set by Burström et al. [33] and the English value set by Devlin et al. [34] as comparisons. QALYs were calculated by combining health state values with duration in time. The maximum number of QALYs that could be gained were 1.5 (since the time horizon was 18 months). EQ VAS was used to measure the overall health on a scale from 0 to 100, where endpoints were the worst health and the best health you can imagine.

**Statistical analyses**

Analyses were performed in IBM SPSS statistics 28 and conducted according to intention-to-treat. A statistical level of \( p \leq 0.05 \) was considered significant. Descriptive statistics were used to compared background characteristics between HI and LMI, and between participants with complete or incomplete data. Missing values of the EQ-5D-5L value set (2% of the observations) were imputed using the last observation carried forward (LOCF) method. Differences between groups were compared using independent sample t-test for QALYs, costs and health state values. Mann-Whitney U-test was used to compare differences in distribution of EQ-5D-5L dimensions of health and ANCOVA for EQ VAS (adjusted for baseline measurement) between groups. Within group differences over time were analysed using paired samples t-test for the health state values and Wilcoxon matched-pairs test for the distribution of the EQ-5D-5L dimensions. The cost-effectiveness, as evaluated by the incremental cost-effectiveness ratios (ICERs), were calculated by dividing the difference in the total costs by the difference in health outcome (QALY) between the groups [1]. The uncertainty around the ICERs was estimated both from a societal and a health care perspective in Microsoft Excel 2016 using bootstrap intervals (10,000 replications) with the use of probabilistic sensitivity analyses, and cost-effectiveness planes were constructed. In addition, deterministic sensitivity analyses were performed with all Phys-Can participants with complete cost measures in the RCT (HI: \( n = 269 \) and LMI: \( n = 265 \)) [18].

**Results**

The response rate was 98% on the EQ-5D-5L questionnaire of the participants included in this study (Figure 1).

**Table 1. Background characteristics at baseline in the HI and LMI exercise group.**

<table>
<thead>
<tr>
<th></th>
<th>HI (n = 99)</th>
<th>LMI (n = 90)</th>
<th>( p ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>61.5 (12.2)</td>
<td>60.3 (11.5)</td>
<td>.511</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>.673</td>
</tr>
<tr>
<td>Female</td>
<td>71 (71.7)</td>
<td>67 (74.4)</td>
<td></td>
</tr>
<tr>
<td>Living situation</td>
<td></td>
<td>.126</td>
<td></td>
</tr>
<tr>
<td>Living with partner</td>
<td>74 (74.7)</td>
<td>73 (83.9)</td>
<td>.785</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University</td>
<td>66 (66.7)</td>
<td>57 (64.8)</td>
<td></td>
</tr>
<tr>
<td>Working situation</td>
<td></td>
<td>.911</td>
<td></td>
</tr>
<tr>
<td>Any sick leave</td>
<td>25 (25.8)</td>
<td>25 (28.1)</td>
<td></td>
</tr>
<tr>
<td>Employed (not on sick leave)</td>
<td>30 (31.0)</td>
<td>28 (31.5)</td>
<td></td>
</tr>
<tr>
<td>Retired</td>
<td>42 (43.3)</td>
<td>35 (39.3)</td>
<td></td>
</tr>
<tr>
<td>Student</td>
<td>0 (0)</td>
<td>1 (1.1)</td>
<td></td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td>.678</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>40 (43.0)</td>
<td>31 (36.0)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>28 (30.1)</td>
<td>25 (29.1)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>17 (18.3)</td>
<td>21 (24.4)</td>
<td></td>
</tr>
<tr>
<td>&lt;3</td>
<td>8 (8.6)</td>
<td>9 (10.5)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>71 (71.7)</td>
<td>66 (73.3)</td>
<td></td>
</tr>
<tr>
<td>T in situ-T1</td>
<td>53 (74.6)</td>
<td>43 (65.2)</td>
<td></td>
</tr>
<tr>
<td>T2–T3</td>
<td>18 (25.4)</td>
<td>23 (34.8)</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>12 (16.9)</td>
<td>11 (16.7)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy*a</td>
<td>42 (51.9)</td>
<td>39 (48.1)</td>
<td>.978</td>
</tr>
<tr>
<td>Target treatmentb</td>
<td>12 (21.4)</td>
<td>9 (18.4)</td>
<td>.675</td>
</tr>
<tr>
<td>Radiotherapy*c</td>
<td>57 (81.4)</td>
<td>57 (86.4)</td>
<td>.435</td>
</tr>
<tr>
<td>Endocrine treatment</td>
<td>56 (80.0)</td>
<td>50 (75.8)</td>
<td>.551</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>24 (24.2)</td>
<td>21 (23.3)</td>
<td></td>
</tr>
<tr>
<td>T1–T2</td>
<td>20 (83.4)</td>
<td>16 (76.2)</td>
<td></td>
</tr>
<tr>
<td>T3–T4</td>
<td>4 (16.7)</td>
<td>4 (19.1)</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>0 (0)</td>
<td>2 (9.5)</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy*d</td>
<td>24 (100.0)</td>
<td>21 (100.0)</td>
<td>–</td>
</tr>
<tr>
<td>Endocrine treatment</td>
<td>11 (45.8)</td>
<td>10 (50.0)</td>
<td>.783</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>4 (4.0)</td>
<td>3 (3.3)</td>
<td></td>
</tr>
<tr>
<td>T2–T4</td>
<td>4 (100.0)</td>
<td>3 (100.0)</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>3 (75.0)</td>
<td>2 (66.7)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy*a</td>
<td>4 (100.0)</td>
<td>3 (100.0)</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: Data are mean (SD) or number (%). \( N \) vary due to missing data, % is of those with data available.

Abbreviations: HI: high-intensity exercise; LMI: low-to-moderate-intensity exercise; T: tumour size; N: lymph node status.

*Adjuvant or neoadjuvant anthracycline-based and/or taxane-based.

*Trastuzumab single or combined with pertuzumab.

*Breast and/or axilla.

*Brachy and/or external.

*Oxaliplatin and/or capcitabine.

Background characteristics of the participants were similar between HI and LMI (Table 1). The majority were women with breast cancer. More than half of the participants had employment and at least one comorbid condition at baseline. No mortality was reported in either HI or LMI group.

**Cost measures**

The total cost was €27,314 (SD: €26,105) per participant in the HI group and €29,788 (SD: €27,517) in the LMI group at the 12-month follow-up and did not differ significantly between the groups (mean cost difference €–2474; 95% CI: (−10,170 to 5243). There were no significant differences in costs between the cost categories; exercise intervention, health care and productivity loss (Table 2).

**Health outcomes**

At the 12-month follow-up, QALYs did not differ significantly between the intensity groups (95% CI: −0.058 to 0.067). On average, the HI group generated 1.190 (SD = 0.223) QALYs
and the LMI group 1.185 (SD = 0.211) QALYs. There was no significant difference between the intensity groups over time in health state values for any of the value sets or in the five single dimensions of health in EQ-5D-5L. For EQ VAS, HI scored better overall health than LMI at baseline (mean diff 6; \( p = .026 \)), no other significant differences were found (Table 3).

No significant changes over time in health state values were found within either HI or LMI. EQ VAS improved significantly from baseline to 12-month follow-up in both HI (mean diff 4.3; \( p = .011 \)) and LMI (mean diff 7.5; \( p < .001 \)). At 12-month follow-up, HI scored worse on mobility (\( p < .001 \)) and pain/discomfort (\( p = .004 \), while both intensity groups scored reduced anxiety/depression (HI: \( p = .001 \) and LMI: \( p < .001 \)) compared to baseline (Figure 2).

### Cost-effectiveness

The ICER provides a ratio of additional cost per unit of health outcome in HI exercise vs LMI exercise. The mean ICER of HI compared with LMI was -516,698, but there was no significant difference in either total cost or in effects between the intensity groups.

### Sensitivity analyses

Bootstrap analysis showed that the ICER was dominant in 56% of the 10,000 replications, meaning that HI was more effective and cost less than LMI. The uncertainty around the ICER for QALYs gained from HI vs LMI exercise are large (Figure 3). However, there was also a 12% risk that HI generated higher costs and less effects compared with LMI. From a health care perspective, the ICER was dominant in 54% of the 10,000 replications. Furthermore, there was no significant difference between the exercise intensities in total cost (mean HI: €35,519 and LMI: €33,387) or in QALYs (HI: 1.189 and LMI 1.190) after including all participants.

### Discussion

HI exercise during oncological treatment appears to be cost-effective compared to LMI exercise at longer term, as HI showed a tendency of lower costs and similar health outcomes compared to LMI. However, there was a large uncertainty around the ICER and no significant difference in costs or in QALYS between the exercise intensities. As previous studies have shown that exercise is cost effective compared to usual care [12–14], our findings support the implementation of exercise regardless of intensity during oncological treatment.

Our result indicates that HI may be cost-effective compared to LMI, in line with the findings of the Kampshoff et al. study [16]. However, their study evaluated a shorter exercise intervention of 12 weeks after oncological treatment and is not directly comparable with our study. A previous systematic review that included seven studies of cost-effectiveness on exercise interventions in cancer survivors concluded that high-intensity exercise may be more cost-effective than low-intensity exercise when compared to usual care [12]. Thus, our finding adds to the previous findings that high intensity exercise might be cost-effective compared to low-to-moderate intensity during oncological treatment. However, there was a high degree of uncertainty around the ICER in our study, thus our results must be interpreted with caution. Also, we included only 33% participants of PhysCan, but sensitivity analyses showed no significant differences in costs or in effects between the exercise intensities after including all participants with complete cost data in the analysis [18]. Hence, we suggest well-designed RCT to evaluate the cost-effectiveness between different exercise intensities to make these results more robust.

The exercise intensity does not seem to have an impact on the total costs during oncology treatment in our study, in line with the results in the Kampshoff et al. [16]. While we found no differences in costs in either health care, productivity loss or intervention between the exercise intensities, the Kampshoff et al. study demonstrated lower health care costs...
and higher intervention costs in the high intensity exercise compared to the low-to-moderate intensity exercise. However, these studies are not directly comparable, and it is also difficult to compare studies with different health care systems and/or payment structures. Yet, it has been shown that no difference in total costs was found between exercise interventions and usual care in the van Waart et al. study [15] and in a recent study anchored in Phys-Can [18]. This means that implementing exercise programmes of either HI or LMI in cancer care does not seem to add nor save costs during treatment.

The health outcomes analysed in this study did not differ between the exercise intensities at post-intervention and in the long-term (12 months after the intervention), which is consistent to earlier findings from the Phys-Can which revealed no statistically significant difference between HI and LMI with regard to HRQoL [19]. The lack of significant differences might be due to the exercise programme in Phys-Can being very comprehensive, and both exercise intensities consisting of combined endurance and resistance training. Thus, while HI exercise was more effective in improving strength and cardiorespiratory fitness and reducing physical fatigue compared to LMI at postintervention in Phys-Can [17], exercise intensity may be important to some but not all outcomes in patients undergoing oncological treatment, but this needs to be further illuminated in forthcoming studies. Furthermore, no significant differences were found over time in health state values at either intensity. Both exercise intensities might be successful in preventing a decline in health state value, but the lack of a control group with no exercise intervention hindered us in drawing conclusions on the effect of exercise on health state over time. However, a previous study within the Phys-Can project showed improvements in aspects of HRQoL at both exercise intensities compared to usual care [19]. Also, participants in the present study already had rather high health state values at baseline.

Figure 2. Proportion of responses by level of severity for EQ-5D-5L dimensions at baseline (M0), post intervention (M6) and 12-month follow up (M18) in the high intensity (HI) and low-to-moderate (LMI) exercise group. Level 1: no problems, level 2: slight problems, level 3: moderate problems, level 4: severe problems, level 5: extreme problems or unable.
Devlin et al. [34] were hypothetically based on health state.

ber of participants with missing EQ-5D-5L data at 12-month follow up which resulted in loss of power. Also, the LOCF imputation method might have introduced bias in the results as the missing values remained constant. Furthermore, Phys-Can RCT was designed to primarily study the effect of HI and LMI exercise on fatigue and secondarily cost-effectiveness. Thus, it is possible that the significance of exercise intensity to cost-effectiveness might be underestimated in the present study. Other limitations were a lack of data on visits to primary care, use of medication not prescribed and short-term sick leave. However, the participants in this study were scheduled for oncological treatment and therefore patients that were attached a hospital trajectory. Therefore, visits to primary care might account for a smaller share of the total health care consumption. The majority of participants were highly educated women with breast cancer; thus, our results might not be generalisable to other cancer populations. Also, our results might not be applicable to other countries with different health care systems and/or payment structures.

**Conclusion**

We concluded that HI and LMI exercise have similar costs and effects during oncological treatment. Hence, based on cost-effectiveness, we suggest that decision makers and clinicians can consider implementing both HI and LMI exercise programmes and recommend either intensity to the patients with cancer during oncological treatment according to their own preferences to facilitate improvement of health.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by grants from the Swedish Cancer Society; the Swedish Research Council, and the Region Östergötland, Sweden.

**ORCID**

Anna-Karin Ax [http://orcid.org/0000-0002-4633-0975](http://orcid.org/0000-0002-4633-0975)

Magnus Husberg [http://orcid.org/0000-0002-3057-8933](http://orcid.org/0000-0002-3057-8933)

Birgitta Johansson [http://orcid.org/0000-0001-6226-6849](http://orcid.org/0000-0001-6226-6849)

Ingrid Demmelmaier [http://orcid.org/0000-0002-2068-4708](http://orcid.org/0000-0002-2068-4708)

Sveinung Berntsen [http://orcid.org/0000-0002-8250-4768](http://orcid.org/0000-0002-8250-4768)

Susanne Björjeson [http://orcid.org/0000-0002-9786-7326](http://orcid.org/0000-0002-9786-7326)

Karin Nordin [http://orcid.org/0000-0001-8685-3722](http://orcid.org/0000-0001-8685-3722)

Thomas Davidson [http://orcid.org/0000-0002-9399-2573](http://orcid.org/0000-0002-9399-2573)

**Data availability statement**

The data that support the findings of this study are available from the corresponding author, [AA], upon reasonable request.

**References**


